Celltrion Wins Approval for Change in European Phase 3 Trial Plan for Darzalex Biosimilar 'CT-P44'… EMA Clears Parts 1 and 2 Simultaneously
Celltrion announced that it has received approval for its application to change the European Phase 3 clinical trial plan (Parts 1 and 2) for its Darzalex biosimilar 'CT-P44'. According to the regulatory filing, this trial is a global Phase 3 clinical study comparing the efficacy and safety of CT-P4

Celltrion announced that it has received approval for its application to change the European Phase 3 clinical trial plan (Parts 1 and 2) for its Darzalex biosimilar 'CT-P44'.
According to the regulatory filing, this trial is a global Phase 3 clinical study comparing the efficacy and safety of CT-P44 and Darzalex Faspro in patients with refractory or relapsed multiple myeloma. The trial will be conducted in combination with lenalidomide and dexamethasone using a double-blind, randomized, active-controlled, parallel-group design, with 394 subjects and a trial period of two years.
■ EMA Application Filed July 13… Approved September 18
The application for the change in the clinical trial plan was submitted on July 13, with approval granted on September 18 (local time). The application agency was the European Medicines Agency (EMA), and the EU CT registration number is '2024-518588-36-00'.
Celltrion stated that through this Phase 3 trial, it plans to demonstrate biosimilarity by comparing the efficacy and safety results of CT-P44 with those of the original drug Darzalex.
■ Simultaneous Approval of Parts 1 and 2… CTIS Approval Confirmed on September 21
Under the revised European Clinical Trials Regulation, effective January 31, 2023, the application and approval process for European clinical trial plans is divided into Part 1, which evaluates clinical design and research methodology, and Part 2, which evaluates clinical institutions and implementation. The company explained that the trial can only proceed once approval through Part 2 is finalized, and that this announcement pertains to the simultaneous approval of both Part 1 and Part 2 of the European Phase 3 trial plan.
Celltrion stated that the date it confirmed the clinical trial plan approval in CTIS (Clinical Trial Information System) was September 21.
■ "Probability of Final Approval for Clinical Trial Drug About 10%… Exercise Caution in Investment"
Celltrion noted an investment caution that the probability of a clinical trial drug ultimately receiving final approval as a medicine is statistically known to be around 10%, and that the commercialization plan may be changed or abandoned depending on the outcomes of the clinical trial and product approval processes.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)


